Idexx Laboratories Free cash flow decreased by 28.2% to $234.26M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 12.7%, from $207.94M to $234.26M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 13.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests strong operational efficiency and the ability to self-fund future innovation or return capital to shareholders, while a decrease may indicate heavy capital expenditure cycles or declining operational profitability.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
High-growth semiconductor and AI infrastructure peers typically prioritize reinvestment, so free cash flow margins are often compared against R&D intensity and capital expenditure requirements of industry rivals.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $211.37M | $142.19M | $178.18M | $82.87M | $35.76M | $151.32M | $124.20M | $144.40M | $172.84M | $238.34M | $217.30M | $168.31M | $215.01M | $191.99M | $232.77M | $207.94M | $151.64M | $371.23M | $326.33M | $234.26M |
| QoQ Change | — | -32.7% | +25.3% | -53.5% | -56.8% | +323.1% | -17.9% | +16.3% | +19.7% | +37.9% | -8.8% | -22.5% | +27.7% | -10.7% | +21.2% | -10.7% | -27.1% | +144.8% | -12.1% | -28.2% |
| YoY Change | — | — | — | — | -83.1% | +6.4% | -30.3% | +74.3% | +383.3% | +57.5% | +75.0% | +16.6% | +24.4% | -19.4% | +7.1% | +23.5% | -29.5% | +93.4% | +40.2% | +12.7% |